OncoMatch/Clinical Trials/NCT07306624
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
Is NCT07306624 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nelmastobart and Docetaxel for non small cell lung cancer.
Treatment: Nelmastobart and Docetaxel — A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Required: BTN1A1 TPS score ≥50 (TPS ≥50)
BTN1A1 TPS score ≥50
Allowed: AGA positive
Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy AND at least 1 locally approved targeted therapy appropriate to the AGA
Allowed: AGA negative
Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or platinum-based chemotherapy
Disease stage
Required: Stage IIIB, IIIC, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy
Must have received: immunotherapy
Subjects with positive AGA must have progressed after At least 1 platinum-based chemotherapy and/or immunotherapy
Must have received: targeted therapy
at least 1 locally approved targeted therapy appropriate to the AGA
Must have received: PD-1/PD-L1 therapy
Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or platinum-based chemotherapy
Must have received: platinum-based chemotherapy
Subjects with negative AGA must have progressed after prior PD1/ (PDL therapy and/or platinum-based chemotherapy
Cannot have received: Docetaxel (Docetaxel)
Exception: for palliative therapy
History of using Docetaxel for palliative therapy
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days
Prior treatment with Cytotoxic chemotherapy or oral targeted therapy within 14 days
Cannot have received: oral targeted therapy
Exception: within 14 days
Prior treatment with Cytotoxic chemotherapy or oral targeted therapy within 14 days
Cannot have received: monoclonal antibody
Exception: within 4 weeks
Monoclonal antibodies or ADCs within 4 weeks
Cannot have received: antibody-drug conjugate
Exception: within 4 weeks
Monoclonal antibodies or ADCs within 4 weeks
Cannot have received: investigational drug
Exception: within 5 half-lives
Investigational drugs within 5 half-lives
Cannot have received: wide-field bone marrow radiation
Exception: within 4 weeks
Wide-field bone marrow radiation (>30%) within 4 weeks
Cannot have received: limited palliative radiation
Exception: within 2 weeks
limited palliative radiation within 2 weeks
Cannot have received: major surgery
Exception: within 4 weeks or incomplete recovery
Major surgery within 4 weeks or incomplete recovery from surgical side effects
Lab requirements
Blood counts
Adequate organ function as described in the protocol
Kidney function
Adequate organ function as described in the protocol
Liver function
Adequate organ function as described in the protocol
Cardiac function
Adequate cardiac function as described in the protocol
Adequate organ function as described in the protocol; Adequate cardiac function as described in the protocol
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify